Comparative antimicrobial activity and mechanism of action of bovine lactoferricin-derived synthetic peptides

Biology of Metals - Tập 24 - Trang 1069-1078 - 2011
Yifan Liu1, Feifei Han1, Yonggang Xie1, Yizhen Wang1
1National Engineering Laboratory of Biological Feed Safety and Pollution Prevention and Control, The Key Laboratory of Molecular Animal Nutrition of Ministry of Education, The Key Laboratory of Feed and Animal Nutrition of Zhejiang Province, Institute of Feed Science, Zhejiang University, Hangzhou, People’s Republic of China

Tóm tắt

Lactoferricin B (LfcinB), a 25 residue peptide derived from the N-terminal of bovine lactoferrin (bLF), causes depolarization of the cytoplasmic membrane in susceptible bacteria. Its mechanism of action, however, still needs to be elucidated. In the present study, synthetic LfcinB (without a disulfide bridge) and LfcinB (C–C; with a disulfide bridge) as well as three derivatives with 15-, 11- and 9-residue peptides were prepared to investigate their antimicrobial nature and mechanisms. The antimicrobial properties were measured via minimum inhibitory concentration (MIC) determinations, killing kinetics assays and synergy testing, and hemolytic activities were assessed by hemoglobin release. Finally, the morphology of peptide-treated bacteria was determined by atomic force microscopy (AFM). We found that there was no difference in MICs between LfcinB and LfcinB (C–C). Among the derivatives, only LfcinB15 maintained nearly the same level as LfcinB, in the MIC range of 16–128 μg/ml, and the MICs of LfcinB11 (64–256 μg/ml) were 4 times more than LfcinB, while LfcinB9 exhibited the lowest antimicrobial activity. When treated at MIC for 1 h, many blebs were formed and holes of various sizes appeared on the cell surface, but the cell still maintained its integrity. This suggested that LfcinB had a major permeability effect on the cytoplasmic membrane of both Gram-positive and Gram-negative bacteria, which also indicated it may be a possible intracellular target. Among the tested antibiotics, aureomycin increased the bactericidal activity of LfcinB against E. coli, S. aureus and P. aeruginosa, but neomycin did not have such an effect. We also found that the combination of cecropin A and LfcinB had synergistic effects against E. coli.

Tài liệu tham khảo

Bellamy W, Takase M, Wakabayashi H et al (1992) Antibacterial spectrum of lactoferricin B, a potent bactericidal peptide derived from the N-terminal region of bovine lactoferrin. J Appl Bacteriol 73(6):472–479 Boman HG (2003) Antibacterial peptides: basic facts and emerging concepts. J Intern Med 254(3):197–215 Eliassen LT, Berge G, Leknessund A et al (2006) The antimicrobial peptide, lactoferricin B, is cytotoxic to neuroblastoma cells in vitro and inhibits xenograft growth in vivo. Int J Cancer 119(3):493–500 Giacometti A, Cirioni O, Prete MS et al (2000) Combination studies between polycationic peptides and clinically used antibiotics against Gram-positive and Gram-negative bacteria. Peptides 21(8):1155–1160 Gifford JL, Hunter HN, Vogel HJ (2005) Lactoferricin: a lactoferrin-derived peptide with antimicrobial, antiviral, antitumor and immunological properties. Cell Mol Life Sci 62(22):2588–2598 Groenink J, Walgreen-Weterings E, van’t Hof W et al (1999) Cationic amphipathic peptides, derived from bovine and human lactoferrins, with antimicrobial activity against oral pathogens. FEMS Microbiol Lett 179(2):217–222 Hancock RE, Sahl HG (2006) Antimicrobial and host-defense peptides as new anti-infective therapeutic strategies. Nat Biotechnol 24(12):1551–1557 Haukland HH, Ulvatne H, Sandvik K et al (2001) The antimicrobial peptides lactoferricin B and magainin 2 cross over the bacterial cytoplasmic membrane and reside in the cytoplasm. FEBS Lett 208(3):389–393 Hwang PM, Zhou N, Shan X et al (1998) Three-dimensional solution structure of lactoferricin B, an antimicrobial peptide derived from bovine lactoferrin. Biochemistry 37(12):4288–4298 Isidra Recio, Servaas Visser (2000) Antibacterial and binding characteristics of bovine, ovine and caprine lactoferricins: a comparative study. Int Dairy J 10(9):597–605 Jenssen H, Adersen JH, Uhlin-Hansen L et al (2004) Anti-HSV activity of lactoferricin analogues is only partly related to their affinity for heparin sulfate. Antivir Res 61(2):101–109 Li A, Lee PY, Ho B et al (2007) Atomic force microscopy study of the antimicrobial action of Sushi peptides on Gram negative bacteria. Biochim Biophys Acta 1768(3):411–418 Nguyen LT, Schibli DJ, Vogel HJ (2005) Structural studies and model membrane interactions of two peptides derived from bovine lactoferricin. J Peptide Sci 11(7):379–389 Nguyen LT, Chau JK, Perry NA et al (2010) Serum stabilities of short tryptophan- and arginine- rich antimicrobial peptide analogs. PLoS One 5(9):e12684 Orsi N (2004) The antimicrobial activity of lactoferrin: current status and perspectives. Biometals 17(3):189–196 Park CB, Kim HS, Kim SC (1998) Mechanism of action of the antimicrobial peptide buforin II: bufrrinII kills microorganisms by penetrating the cell membrane and inhibiting cellular functions. Biochem Biophys Res Commun 244(1):253–257 Schibli DJ, Hwang PM, Vogel HJ (1999) The structure of the antimicrobial active center of lactoferricin B bound to sodium dodecyl sulfate micelles. FEBS Lett 446(2–3):213–217 Tolokh IS, Vivcharuk V, Tomberli B, et al (2009) Binding free energy and counterion release for adsorption of the antimicrobial peptide lactoferricin B on a POPG membrane. Phys Rev E Stat Nonlin Soft Matter phys 80(3 Pt 1):031911 Tomita M, Takase M, Bellamy W et al (1994) A review: the active peptide of lactoferrin. Acta Paediatr Jpn 36(5):585–591 Ueta E, Tanida T, Osaki T (2001) A novel bovine lactoferrin peptide, FKCRRWQWRM, suppresses Candida cell growth and activates neutrophils. J Peptide Res 57(3):240–249 Ulvatne H, Vorland LH (2001) Bactericidal kinetics of 3 lactoferricins against Staphylococcus aureus and Escherichia coli. Scand J Infect Dis 33(7):507–511 Ulvatne H, Haukland HH, Olsvik Ø, Vorland LH (2001) Lactoferricin B causes depolarization of the cytoplasmic membrane of Escherichia coli ATCC 25922 and fusion of negatively charged liposomes. FEBS Lett 492(1–2):62–65 Ulvatne H, Samuelsen Ø, Haukland HH et al (2004) Lactoferricin B inhibits bacterial macromolecular synthesis in Escherichia coli and Bacillus subtilis. FEMS Microbiol Lett 237(2):377–384 Umeyama M, Atsushi Kira, Nishimura K et al (2006) Interactions of bovine lactoferricin with acidic phospholipids bilayers and its antimicrobial activity as studied by solid-state NMR Biochim. Biophys Acta 1758(9):1523–1528 Van der Kraan Mi, Groenink J, Nazmi K et al (2004) Lactoferrampin: a novel antimicrobial peptide in the N1-domain of bovine lactoferrin. Peptides 25(2):177–183 Vorland LH, Osbakk SA, Perstølen T et al (1999) Interference of the antimicrobial peptide lactoferricin B with the action of various antibiotics against E coli and S aureus. Scand J Infect Dis 31(2):173–177 Wakabayashi H, Matsumoto H, Hashimoto K et al (1999) N-Acylated and d enantiomer derivatives of a nonamer core peptide of lactoferricin B showing improved antimicrobial activity. Antimicrob Agents Chemother 43(5):1267–1269 Wakabayashi H, Teraguchi S, Tamura Y (2002) Increased Staphylococcus-killing activity of an antimicrobial peptide, Lactoferricin B, with minocycline and monoacylglycerol. Biosci Biotechnol Biochem 66(10):2161–2167 Zhang TN, Yang W, Liu N (2010) Effect of loop structure of bovine lactoferricin on apoptosis in Jurkat cells. Biometals 23(3):555–561